The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Arobase: A phase III trial of exemestane (Exe) and bevacizumab (BEV) as maintenance therapy in patients (pts) with metastatic breast cancer (MBC) treated in first line with paclitaxel (P) and BEV—A Gineco study.
Olivier Tredan
Research Funding - Roche
Philippe Follana
No relevant relationships to disclose
Isabelle Moullet
No relevant relationships to disclose
Claire Cropet
No relevant relationships to disclose
Stéphanie Trager-Maury
No relevant relationships to disclose
Jérôme Dauba
No relevant relationships to disclose
Sandrine Lavau-Denes
No relevant relationships to disclose
Veronique Dieras
Consultant or Advisory Role - Roche/Genentech
Honoraria - Roche/Genentech
Dominique Beal-Ardisson
No relevant relationships to disclose
Marie-Claude Gouttebel
No relevant relationships to disclose
Hubert Orfeuvre
No relevant relationships to disclose
Eric Pujade-Lauraine
No relevant relationships to disclose
Thomas Denis Bachelot
Consultant or Advisory Role - Roche
Research Funding - Roche